Trial Condition(s):
Prevention of venous thromboembolism after MOS
BAY59-7939,Dose proportionality II for SPAF
Bayer Identifier:
12362
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
24
Trial Dates
Phase
1
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
N/A
Where to Participate
Loading...
Locations
Status
| Locations | Status | |
|---|---|---|
Locations CRS Clinical-Research-Services Mannheim GmbH Mannheim, Germany, 68167 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
For details, please refer to trial results
Additional Information
Copyright © Bayer
Powered by
